Title:
【発明の名称】酸化窒素シンターゼ阻害剤としてのサイクリックアミジンアナログ
Document Type and Number:
Japanese Patent JPH10509150
Kind Code:
A
Abstract:
Disclosed herein are compounds of Formula I I and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These disease and disorders include hypotension, septic shock, toxic shock syndrom, hemodialysis, IL-2 therapy such as in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn or psoriasis and respiratory conditions such as bronchitis, asthma, and acure respiratory distress (ARDS), myocarditis, heart failure, atherosclerosis, arthritis, rheumatoid arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis. Compounds of Formula I are also usful in the treatment of hypoxia, hyperbaric oxygen convulsions and toxicity, dementia, Sydenham's chorea, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, mulitple sclerosis, Korsakoff's disease, imbecility related to cerebral vessel disorder, ischemic brain edema, sleeping disorders, schizophrenia, depression, PMS, anxiety, drug addiction, pain, migraine, immune complex disease, as immunosupressive agents and for preventing or reversing tolerance to opiates and diazepines.
More Like This:
Inventors:
Rabindra N, Gusikonda
Grant, Stephen Kay
Matsukos, Malcolm
Shear, Shirenitz Kay
Siyan Karan, Kosanda Raman
Caldwell, Charles G
Deulette, Philip L
Grant, Stephen Kay
Matsukos, Malcolm
Shear, Shirenitz Kay
Siyan Karan, Kosanda Raman
Caldwell, Charles G
Deulette, Philip L
Application Number:
JP51628596A
Publication Date:
September 08, 1998
Filing Date:
November 13, 1995
Export Citation:
Assignee:
Merck End Company, Inc.
International Classes:
A61K31/395; A61K31/40; A61K31/403; A61K31/4035; A61K31/435; A61K31/445; A61K31/4458; A61K31/451; A61K31/47; A61K31/473; A61K31/54; A61K31/5415; A61K31/55; A61K31/554; A61P1/00; A61P11/00; A61P25/00; A61P29/00; A61P37/00; C07D215/36; A61P43/00; C07D207/22; C07D209/44; C07D211/72; C07D211/74; C07D211/76; C07D211/78; C07D215/38; C07D219/12; C07D221/04; C07D221/16; C07D223/12; C07D225/02; C07D241/06; C07D241/44; C07D243/08; C07D243/14; C07D265/36; C07D267/10; C07D279/12; C07D279/16; C07D281/06; C07D471/04; C07D487/04; C07D491/04; (IPC1-7): C07D207/22; A61K31/395; A61K31/40; A61K31/435; A61K31/445; A61K31/47; A61K31/54; A61K31/55; C07D209/44; C07D211/72; C07D211/74; C07D211/76; C07D215/36; C07D219/12; C07D221/16; C07D223/12; C07D225/02; C07D279/16; C07D281/06
Attorney, Agent or Firm:
Yoshio Kawaguchi (3 outside)